Profile data is unavailable for this security.
About the company
Alkem Laboratories Ltd. is an India-based pharmaceutical company with global operations, engaged in the development, manufacturing and sale of pharmaceutical and nutraceutical products. The Company produces branded generics, generic drugs, active pharmaceutical ingredients (APIs) and nutraceuticals, which it markets in India and international markets. It has a portfolio of more than 800 brands in India. The Company also has a presence in more than 40 international markets, with the United States being its key focus market. Its offerings include therapies, Rx products and Alkem generic. Its therapy offerings include anti-infective, anti-osteoporosis, cardiology, neurology, dermatology, diabetology, gastroenterology, gynecology, oncology, ophthalmology, respiratory, rheumatology and urology. Its product portfolio also includes mega-brands such as Clavam, Pan, Pan-D, and Taxim-O. Under the Alkem Generics cluster there are four divisions: Futura, Maxxio, Novokem and Alkem Healthcare.
- Revenue in INR (TTM)126.68bn
- Net income in INR17.96bn
- Incorporated1973
- Employees16.87k
- LocationAlkem Laboratories LtdAlmac House, Senapati Bapat MargMUMBAI 400013IndiaIND
- Phone+91 2 239829999
- Fax+91 2 224927190
- Websitehttps://www.alkemlabs.com/
Peer analysis
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Glenmark Pharmaceuticals Ltd | 118.13bn | -18.99bn | 349.11bn | 15.56k | -- | 4.45 | -- | 2.96 | -67.28 | -53.21 | 418.40 | 278.11 | 0.7004 | 1.81 | 4.28 | -- | -10.86 | 1.02 | -15.92 | 1.43 | 62.64 | 61.27 | -15.50 | 1.43 | 0.8447 | 1.19 | 0.1356 | 56.98 | 1.98 | 3.67 | -1,018.93 | -- | -5.89 | 4.56 |
| Biocon Ltd | 147.56bn | 10.23bn | 400.69bn | 3.41k | 39.20 | 2.03 | 13.98 | 2.72 | 8.54 | 8.54 | 123.32 | 164.78 | 0.273 | 1.07 | 3.01 | -- | 2.40 | 3.20 | 3.50 | 4.48 | 66.81 | 63.27 | 8.80 | 9.37 | 0.6664 | 1.63 | 0.3917 | 8.22 | 32.05 | 21.76 | 120.99 | 2.46 | 5.30 | 0.00 |
| GlaxoSmithKline Pharmaceuticals Limited | 34.54bn | 5.90bn | 449.75bn | 3.21k | 76.24 | 25.30 | 68.18 | 13.02 | 34.82 | 34.82 | 203.88 | 104.93 | 1.00 | 2.71 | 16.67 | 10,755,860.00 | 17.14 | 11.01 | 29.26 | 17.88 | 61.36 | 55.77 | 17.08 | 12.25 | 1.49 | 466.45 | 0.0104 | 192.07 | 6.21 | 2.00 | -2.91 | 5.78 | -36.02 | 9.86 |
| Alkem Laboratories Ltd | 126.68bn | 17.96bn | 610.01bn | 16.87k | 33.97 | 5.91 | 28.90 | 4.82 | 150.19 | 150.19 | 1,059.44 | 862.57 | 0.8638 | 1.87 | 5.78 | -- | 12.35 | 11.88 | 17.39 | 17.50 | 61.02 | 59.43 | 14.30 | 13.94 | 1.94 | 8.32 | 0.1169 | 25.80 | 9.21 | 11.48 | 82.47 | 18.75 | -13.30 | 20.11 |
| Lupin Ltd | 200.11bn | 19.14bn | 731.27bn | 18.97k | 38.29 | 5.12 | 23.35 | 3.65 | 41.89 | 41.89 | 437.85 | 313.60 | 0.8524 | 1.41 | 4.36 | -- | 8.24 | 1.43 | 13.34 | 2.22 | 66.80 | 59.70 | 9.67 | 2.04 | 0.9991 | 8.64 | 0.1689 | 79.28 | 20.25 | 6.41 | 345.15 | 30.18 | -1.17 | 9.86 |
| Aurobindo Pharma Ltd | 290.02bn | 31.73bn | 737.70bn | 15.69k | 23.26 | 2.47 | 15.73 | 2.54 | 54.12 | 54.12 | 494.54 | 509.35 | 0.6827 | 1.38 | 6.25 | -- | 7.46 | 9.24 | 10.35 | 13.43 | 56.54 | 54.15 | 10.93 | 12.72 | 1.18 | 16.12 | 0.1821 | -- | 16.68 | 8.19 | 64.62 | 6.06 | 17.96 | -- |
| Mankind Pharma Ltd | 103.35bn | 19.13bn | 897.66bn | 18.47k | 46.98 | 9.59 | 38.36 | 8.69 | 47.69 | 47.69 | 257.65 | 233.73 | -- | -- | -- | -- | -- | -- | -- | -- | 68.94 | -- | 18.79 | -- | 2.37 | 116.65 | 0.0212 | -- | 18.12 | -- | 49.23 | -- | -- | -- |
| Holder | Shares | % Held |
|---|---|---|
| ICICI Prudential Asset Management Co. Ltd.as of 31 May 2024 | 3.95m | 3.31% |
| DSP Asset Managers Pvt. Ltd.as of 31 May 2024 | 2.81m | 2.35% |
| Life Insurance Corporation of India (Investment Portfolio)as of 30 Jun 2023 | 2.04m | 1.70% |
| The Vanguard Group, Inc.as of 06 Jun 2024 | 1.94m | 1.62% |
| Nippon Life India Asset Management Ltd. (Invt Mgmt)as of 31 May 2024 | 1.77m | 1.48% |
| HDFC Life Insurance Co. Ltd. (Investment Portfolio)as of 31 May 2024 | 1.41m | 1.18% |
| Norges Bank Investment Managementas of 31 Dec 2023 | 1.05m | 0.88% |
| Kotak Mahindra Asset Management Co. Ltd.as of 31 May 2024 | 1.03m | 0.86% |
| Kotak Mahindra Asset Management (Singapore) Pte Ltd.as of 30 Jun 2023 | 974.21k | 0.82% |
| SBI Funds Management Ltd.as of 31 May 2024 | 935.70k | 0.78% |
